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Using rat heart sarcolemma nd liver plasma membrane vesicles, it has been verified that the transport of leukotriene C, (LTC,) across membranes 
is an ATP-dependent process; the apparent K,,, for LTC, was 150 nM (heart sarcolemma) or 250 nM (liver plasma membrane). S-(2,4-dinitrophenyl)- 
glutathione (DNP-SG) inhibited LTC, uptake into the vesicles dose-dependently (I,, = 25 ,uM for both heart sarcolemma nd liver plasma mem- 
brane vesicles). Mutual inhibition between LTC, and DNP-SG in uptake into the vesicles demonstrates that transport of LTC, is mediated by 
an ATP-dependent glutathione S-conjugate carrier. 
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1. INTRODUCTION 
Leukotrienes are a family of biologically active con- 
jugated trienes derived from arachidonic acid via the 
54ipoxygenase pathway, and play an important role in 
disease processes uch as local inflammation, bronchial 
asthma, liver injury, tissue trauma and shock ([l-5] for 
review). The cysteinyl leukotrienes (LTC4, LTD4, and 
LTEh), originally known as SRS-A, increase vascular 
~rmeability and contract smooth muscles [l]. LTC4 is 
formed through the reaction of LTkr with glutathione 
in various organs and cell types IS], and the reaction is 
catalyzed by a microsomal enzyme, leukotriene C4 syn- 
thase, and/or isozymes of cytosolic glutathione S- 
transferases. LTC4, in turn, is converted to LTD4 and 
LTE4 by two extracellular ectoenzymes, i.e. y-glutamyl- 
transferase and dipeptidase, respectively, whereas for 
this conversion LTC4 must be precedently transported 
out of cells. 
the result, it was hypothesized that the ATP-dependent 
carrier would share the translocation of LTC4. The pre- 
sent study has been undertaken to examine this hypo- 
thesis using plasma membrane vesicles prepared from 
rat heart and liver. We now provide evidence for the 
first time that LTC4, transport is an ATP-dependent 
process mediated by the glutathione S-conjugate car- 
rier. 
Recently, it has been demonstrated that transport of 
glutathione S-conjugate, i.e. DNP-SG, across rat liver 
plasma membrane as well as rat heart sarcolemma is 
mediated by an ATP-dependent carrier [6-91. In the 
case of heart sarcolemma, the transport of DNP-SG 
was competitively inhibited by LTC4 [9], and based on 
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2. MATERIALS AND METHODS 
2.1. Bioehemiculs 
Leukotrienes CO, D4 and & (Salford Ultrafine Chemicals and 
Research Ltd, Manchester), ATP, creatine phosphate and creatine 
kinase (Boehringer, Manuheim), ouabain (Sigma, St. Louis), 
(14,15-3Hr]leukotriene C4 and ]2-‘Hlglycine-labeled GSH (New 
England Nuclear, Boston) were purchased from the commercial 
sources indicated. [‘H]DNP-SG was enzymatically synthesized as 
described previously f8,9]. Anth~utin and 4-hydroxynonenal are 
generous gifts from Dr T. Komai (Sankyo Co. Ltd, Tokyo, Japan) 
and Prof. H. Esterbauer (Graz Universitat, Austria), respectively. All 
other chemicals were of analytical grade. 
2.2. Pre~ration of sarcolemma vesicles from rat heart and plasma 
membrane vesicles from rat liver 
Rat heart sarcolemma vesicles were prepared as described previous- 
ly [8,9]. Preparation of plasma membrane (a mixture of basolateral 
and canalicular membranes) from rat liver was performed according 
to [lo]. The plasma membran5rich fraction obtained from Percoll- 
gradient centrifugation was suspended in 0.25 M sucrose, 0.5 mM 
CaCla and 5 mM Hepes-KOH (pH 7.4), layered over 38% sucrose, 
and then centrifuged at 105 000 x g for 60 min. The resulting turbid 
layer at the interface was harvested, suspended in 10 ml of 0.25 M 
sucrose containing 10 mM Tris-HCl (pH 7.4), and centrifuged at 
70 100 x g for 30 min. The precipitate was finally suspended in a 
small volume of 0.25 M sucrose containing 10 mM Tris-HCl (pH 7.4), 
frozen in liquid Nz. and stored at - 70°C until use. 
Protein was determined according to Lowry et al. [I 11, 
95 
Volume 259, number 1 FEBS LETTERS December 1989 
2.3. Transport of pH]LTC4 into plasma membrane vesicles 
The standard incubation medium for the measurement of LTCI up- 
take contained membrane vesicles (So-150 pg protein), 12.5 nM 
[‘H]LTCd, 0.25 M sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM ATP, 
1OOpM anthglutin, 10 mM MgClz, 10 mM creatine phosphate and 100 
fig/ml creatine kinase in a final volume of 1 10~1. The incubation was 
carried out at 37°C under Nz gas. Uptake of [‘HILT& into the 
vesicles was measured by a rapid filtration technique using Millipore 
filters (GVWP, 0.22-,um pore size) as described previously [8,9]. 
2.4. High performance liquid chromatography 
The purity of leukotriene samples and metabolites of LTG after in- 
cubation with membrane vesicles was analyzed by HPLC with a 
reverse phase column (Cosmosil 5Cl8, 4.6 x 250 mm, Nacalai Tes- 
que Ltd, Kyoto) according to [12]. The mobile phase (flow rate, 0.8 
ml/min) consisted of methanol/water, 7: 3 (v/v), plus 0.1% acetic 
acid adjusted to pH 5.4 with NH40H. 
To check the decomposition of LTC4 by y-glutamyltransferase of 
membrane vesicles, [‘H]LTG was incubated with vesicles in the stan- 
dard incubation medium at 37°C for 10 min, but no detectable reac- 
tion product was observed on HPLC. 
3. RESULTS 
3.1. A TP-stimulated uptake of L TC4 into heart sar- 
colemma and liver plasma membrane vesicles 
Fig. 1 shows the time courses of LTG uptake into the 
membrane vesicles. Incubation of the vesicles with 12.5 
nM [3LTC4 in the presence of 1 mM ATP resulted in a 
rapid uptake of LTG, and the initial rates were 0.40 
and 1.64 pmol/min per mg protein for rat heart sar- 
colemma and liver plasma membrane vesicles, respec- 
tively. In the control experiment, when the vesicles were 
incubated without ATP, heart sarcolemma vesicles 
took up LTG very slowly (fig.lA), whereas liver 
plasma membrane vesicles howed a transient uptake of 
LTC4 (fig. 1B). 
The stimulation of LTG uptake is specific for ATP; 
ADP, AMP or ATP analogues, i.e. adenosine 5’-p,r- 
methyleneltriphosphate and adenosine 5 ’ -lo,r- 
imidoltriphosphate had no stimulatory effect. 
Vanadate inhibited the ATP-stimulated LTG uptake 
(ISO = 30pM), while ouabain and EGTA did not affect 
the uptake. 
Fig.2 shows the effect of LTC4 concentration on the 
rates of LTG uptake into heart sarcolemma (A) and 
liver plasma membrane (B) vesicles. The uptake rate 
was saturated with respect o LTG concentration. The 
apparent K,,, value for LTC4 was estimated to be 150 
nM, and Vmax was 15 pmol/min per mg protein for 
heart sarcolemma vesicles. Likewise, values of 
K,,, = 250 nM for LTG and Max = 45 pmol/min per 
mg protein were obtained for liver plasma membrane 
vesicles. 
3.2. Inhibition of A TP-stimulated LTG uptake into 
vesicles by glutathione S-conjugates 
ATP-stimulated LTG uptake into heart sarcolemma 
and liver plasma membrane vesicles was dose- 
dependently inhibited by a model glutathione S- 
conjugate, DNP-SG (fig.3); 200 PM DNP-SG inhibited 
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Fig.1. Time courses of LTC., uptake into heart sarcolemma (A) and 
liver plasma membrane (B) vesicles. Heart sarcolemma or liver plas- 
ma membrane vesicles (50 fig protein) were incubated with 12.5 nM 
[‘H]LTG at 37’C in the absence (0) or presence (0) of 1 mM ATP 
in 110 ~1 incubation medium containing 10 mM Tris-HCl (pH 7.4), 
250 mM sucrose, 10 mM creatine phosphate, creatine kinase 
(100 pg/ml) and 10 mM MgClz. LTG incorporated into vesicles was 
determined as described in section 2. Data are expressed as mean + 
SE, n = 3. 
the uptake almost completely. As observed in DNP-SG 
uptake into rat heart sarcolemma vesicles [8], LTG up- 
take into both heart sarcolemma nd liver plasma mem- 
brane vesicles was effectively inhibited by glutathione 
S-conjugates with a long aliphatic carbon chain, e.g. S- 
octyl- and S-decyl-glutathione and glutathione S- 
conjugate of 4-hydroxynonenal (table 1). Non- 
radiolabeled LTG (10 PM) suppressed [3H]LTC4 up- 
take to nearly zero, whereas LTD4 and LTE4 inhibited 
LTC4 uptake by about 30%. 
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Fig.2. Effect of LTG concentration on the rate of ATP-stimulated 
LTG uptake into heart sarcolemma (A) and liver membrane (B) 
vesicles. Vesicles were incubated with [‘H]LTG for 1 min at 37°C 
under the conditions described in fig. 1. ATP-stimulated LTC4 uptake 
was evaluated from the difference in radioactivity incorporated into 
vesicles in the presence and absence of ATP. Data are expressed as 
mean f SE,n=3. 
CNP-SC -(pi ) 
Fig.3. Effect of DNP-SG on ATP-stimulated LTG uptake into heart 
sarcolemma (0) and liver plasma membrane (0) vesicles. Vesicles 
were incubated with 12.5 nM [‘H]LTG in the presence of DNP-SC 
under the conditions described in fig.1. After a 1-min incubation, the 
reaction was terminated, and ATP-stimulated LTCd uptake was 
evaluated from the difference in radioactivity incorporated into 
vesicles in the presence and absence of ATP. 100% uptake rate equals 
0.40 pmol/min per mg protein (heart sarcolemma) and 
1.64 pmol/min per mg protein (liver plasma membrane) determined 
in the control experiments without DNP-SG. Data are expressed as 
the mean value of triplicate measurements. 
Table 1 
Effect of glutathione S-conjugates and cysteinyl leukotrienes on 
LTC4 uptake into heart sarcolemma and liver plasma membrane 
vesicles 
Compound ATP-stimulated 
LTC4 uptake 
pmol/min per mg pro- 
tein (olo inhibition) 
Heart Liver 
None 0.41 ( 0.0) 1.64 ( 0.0) 
S-(2,4_Dinitrophenyl)-glutathione 0.30 (27.7) 1.16 (29.5) 
S-(p-Nitrobenzyl)-glutathione 0.31 (24.9) 1.19 (27.6) 
S-(p-Chlorophenacyl)-glutathione 0.29 (28.6) 1.16 (29.0) 
S-Methylglutathione 0.40 ( 2.5) 1.64 ( 0.2) 
S-Ethylglutathione 0.39 ( 4.1) 1.60 ( 2.4) 
S-Butylglutathione 0.38 ( 7.8) 1.51 ( 8.2) 
S-Hexylglutathione 0.34 (17.8) 1.45 (11.3) 
S-Octylglutathione 0.18 (55.3) 0.81 (50.4) 
S-Decylglutathione 0.04 (89.7) 0.16 (90.4) 
4-Hydroxynonenal-glutathione conjugate 0.13 (68.0) 0.48 (70.9) 
Leukotriene C4 0.01 (98.3) 0.01 (99.1) 
Leukotriene D4 0.29 (29.7) 1.11 (32.4) 
Leukotriene E4 0.31 (24.2) 1.15 (30.0) 
Heart sarcolemma or liver plasma membrane vesicles (50 ,ug protein) 
were incubated with 12.5 nM [‘H]LTG at 37°C for 1 min as de- 
scribed in section 2. The compounds indicated in the table were pres- 
ent at a concentration of 10 pM. Data are presented as mean values 
of triplicate measurements 
4. DISCUSSION 
4.1. Transport of L TC4 across plasma membrane is an 
A TP-dependent process mediated by a glutathione 
S-conjugate carrier 
The present study shows that transport of LTG 
across heart sarcolemma nd liver plasma membrane is 
an ATP-dependent process mediated by a glutathione 
S-conjugate carrier, which is verified by the mutual in- 
hibition between LTG and DNP-SG for the uptake in- 
to the vesicles (fig.3 and [9]) as well as by the inhibition 
of LTG uptake by different types of glutathione S- 
conjugates (table 1). As compared with DNP-SG, LTC4 
is a much better substrate for the ATP-dependent 
glutathione S-conjugate carrier. The K,,, value for LTG 
(150 nM, heart sarcolemma; 250 nM, liver plasma 
membrane) is about two orders of magnitude smaller 
than that for DNP-SG (lo-20 PM, [6-81). At a low con- 
centration of LTC4 (12.5 nM) (fig. l), the rate of LTG 
uptake into heart sarcolemma or liver plasma mem- 
brane vesicles was about 40 times higher than that of 
DNP-SG uptake observed with the same concentration 
of DNP-SG. 
In the liver, cysteinyl leukotrienes and glutathione S- 
conjugates (e.g. DNP-SG and glutathione-conjugated 
bromosulfophthalein) are excreted into bile [ 13-171. 
Biliary excretion of glutathione S-conjugates has been 
shown to be dependent on cytosolic ATP and not to be 
driven by the plasma membrane potential [ 18, cf. 191. A 
hereditary defect in the excretion of organic anions 
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from hepatocytes into bile was discovered in a mutant 
strain of Wistar rats [20], and in the mutant rats, biliary 
transport of both cysteinyl eukotrienes and glutathione 
S-conjugate (DNP-SG) is strongly impaired, whereas 
hepatocellular uptake of LTG from the vascular space 
is normal [21,22]. These findings indicate that biliary 
export systems for glutathione S-conjugate and cys- 
teinyl leukotrienes are closely related or identical to 
each other, being in accordance with our conclusion 
that biliary LTG transport is mediated by the ATP- 
dependent glutathione S-conjugate carrier. 
Hepatocytes, on the other hand, are suggested to 
contain another specific transport system in the baso- 
lateral membrane for uptake of cysteinyl leukotrienes 
from the vascular space into the cells [13-15,231. In this 
case, cysteinyl eukotriene uptake was not interfered by 
glutathione S-conjugate, S-glutathionyl-acetaminophen 
[23], and in this context the transport system is distinct 
from the ATP-dependent glutathione S-conjugate car- 
rier discussed here. 
Cardiac tissue produces LTG [24] and LTC4 release 
from the isolated perfused rat heart was stimulated by 
platelet activating factor [25]. The ATP-dependent 
transport system described here is likely to be responsi- 
ble for the elimination of LTG from heart cells and 
thereby facilitates further metabolism of LTG, namely 
LTD4 and LTE4 formation. It has been reported that 
some arachidonic acid metabolites including LTG in- 
tracellularly modulate the G-protein-gated K+ channel 
[26], indicating a physiological role of LTG as an intra- 
cellular messenger. Existence of an LTG degrading en- 
zyme system in heart cells has not been elucidated. The 
ATP-dependent transport system may play a role in 
regulating intracellular LTC4 concentrations. 
4.2. Concluding remarks 
Lam et al. have most recently reported the existence 
of an LTG export system in human eosinophils which 
might be distinct from the glutathione S-conjugate car- 
rier [27]. It is, therefore, of interest to know what type 
of carrier is responsible for the transport of LTG in 
other LT&producing cells, such as monocytes, mast 
cells, and macrophages. Isolation and characterization 
of the ATP-dependent glutathione S-conjugate carrier 
is the next important step of our study, which would 
facilitate our understanding of the molecular 
mechanism and properties of LTC4 transport in dif- 
ferent tissues and cell types. 
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